Beam Therapeutics (BEAM) Assets (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Assets data on file, last reported at $1.5 billion in Q1 2026.

• Assets for Q1 2026 came in at $1.5 billion, up 0.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 0.95% YoY), and the FY2025 annual result was $1.5 billion, up 34.19% from the prior year.
• Assets steadied at $1.5 billion in Q1 2026 per BEAM's latest filing, from $1.5 billion in the prior quarter.
• Over five years, Assets peaked at $1.5 billion in Q4 2025 and troughed at $1.1 billion in Q4 2024.
• A 5-year average of $1.4 billion and a median of $1.4 billion in 2023 frame the typical range for Assets.
• The sharpest annual moves came in 2022 and 2024: Assets jumped 109.65% in 2022, then retreated 24.38% in 2024.
• A 5-year view of Assets shows it stood at $1.3 billion in 2022, then rose by 8.79% to $1.5 billion in 2023, then retreated by 24.38% to $1.1 billion in 2024, then soared by 34.19% to $1.5 billion in 2025, then slipped by 0.03% to $1.5 billion in 2026.
• Business Quant data shows BEAM's Assets at $1.5 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.3 billion in Q3 2025.